Introduction
In recent years significant advances have been achieved in the treatment of lung cancer resulting in prolonged survival of patients (Dempke 2015; Petrelli et al. 2015 ; Scagliotti et al. 2015) . Frailty status, along with sarcopenia evaluation, partially parallel to determination of performance status (PS), could potentially improve the choice of patients eligible for both initial and further therapy (4). Recently, several publications pointed out low Alanine aminotransferase (ALT) activity in the peripheral blood as a reliable marker for sarcopenia and frailty, associated with shortened life expectancy in several selected populations (5-8). Specifically, low serum ALT activity was found to be associated with shortened survival in middle aged healthy adults (6), and in patients hospitalized for variable causes (5), but not specifically in patients with malignancies. According to conclusions of the publications mentioned above, low ALT values, representing low muscle mass (Sarcopenia) may represent increased frailty and subsequently shortened survival. Since better assessment of frailty can improve decision making in the field of oncology and low ALT has the advantage of being a quantitative parameter in the assessment of frailty, we decided to examine whether low ALT is associated with poor prognosis in patients with advanced lung cancer.
Methods

Patients and clinical parameters
Consecutive lung cancer patients presenting to the Thoracic Oncology Unit at Sheba Medical Center, Israel during a 3 years period (September 2011 through November 2014) were included in the study. Potential prognostic clinical characteristics were extracted from the medical records. Clinical parameters that are prognostic in this population according to previous publications (9-11) were collected, including age and weight at presentation, sex, histologic diagnosis (non-small cell lung cancer; NSCLC, subtypes of adenocarcinoma/squamous cell carcinoma/large cell carcinoma and small cell lung cancer), PS (according to the Eastern Cooperative Oncology Group, ECOG grading), and stage at diagnosis (according to the American Joint Committee on Cancer, 7th version) as well as marital status (categorized as married or not) . We further collected plasma albumin, creatinine, and ALT activity at the time of diagnosis, before treatment initiation. ALT activity was tested as part of routine blood work (using a standard Beckman Coulter®, applying a kinetic UV test), shortly after the initial patient's visit to the Thoracic Oncology Unit. In order to assure maximal catalytic activity of the ALT from the blood drawn, all test tubes were routinely supplemented with activated pyridoxal phosphate (P-5-P), serving as an essential co-factor for ALT catalytic activity. Patients with higher than the upper limit of normal ALT values and patients with missing clinical data were excluded.
The study was approved by the institutional ethics committee. Since this was a retrospective study, written informed consent was not needed.
Statistical analysis
Categorical variables were described using frequency and percentage. Continuous variables were described using mean (standard deviation, SD) for normally distributed variables and median (interquartile range, IQR) for non-normally distributed variables. Correlation between ALT and Continuous variables was evaluated using spearman's correlation coefficient. ALT levels were compared between categorical variables using MannWhitney test or Kruskal -Wallis Test. Univariate COX Regression was used to evaluate the association between ALT and potential confounders and mortality. Multivariate Cox regression was used to evaluate the association between ALT and mortality while controlling for potential confounders. Variables were selected for inclusion in the multivariate regression using backward stepwise (likelihood ratio) method. All analyses involved 2-tailed tests of significance and were performed using SPSS software, version 22 . P values less than 0.05 were considered statistically significant.
Results
Our cohort included 254 patients, out of which 203 patients were eligible for analysis (51 patients were excluded due to ALT levels higher than 40, associated, most probably with hepatitis from various reasons, and because of missing relevant ALT values. Patients' characteristics are presented in table 1. The mean age at the time of cancer diagnosis was 66.6 years. 149 patients (73.4%) were diagnosed in advanced stages (III-IV), nevertheless; most of them (72.9%) had good performance status upon diagnosis (ECOG PS equal or lower than 1). During a median follow-up period of 15.4 months, 79 (38.9%) patients died.
No statistically significant difference was found in the ALT levels between different disease stages: the median ALT activity was 17.0, 15.0, 16.0 and 15.0 IU/L for stages 1 to 4 respectively (p = 0.92). Importantly, ALT blood levels were not found to be associated with patients' ECOG performance status. Additionally, we did not find a significant difference between ALT levels of patients with different histology: The median ALT level was 16 ALT blood levels were not found to have significant correlation with any of the following parameters: serum creatinine level, albumin concentration, weight and age. Those latter parameters were also not associated with increased risk of mortality.
Low ALT activity levels in the peripheral blood (lower than 17 IU/L) were not associated, in a statistically significant manner, with increased risk for mortality (Figure 1) . In a univariate analysis, the following parameters were found to be associated with increased risk of mortality: histologic type compatible with SCLC compared to NSCLC (HR=2.0, CI95% 1.0-3.9; p < 0.05), male sex (HR=2.0, 95% CI 1.3-3.2; p < 0.05), advanced disease stage upon diagnosis (for stage 3 relative to stages 1 & 2, HR=4.6, 95% CI 1.5-13.6, P < 0.05 an for stage 4 relative to stages 1 to 3, HR=10.9, 95% CI 3.8-31.3, p < 0.001), low ECOG PS upon diagnosis (for PS 2, HR=3.9, 95% CI 1.8-6.3; p < 0.001; for PS 3, HR=6.9, 95% CI 3.4-14, p < 0.001 and for PS 4, HR=34.2, 95% CI 7.4-159, p < 0.001). In a multivariate analysis, low ALT levels were not found to be associated with increased mortality. Variables that were found to be associated with increased risk of mortality on multivariate analysis (Table 2) were male sex (HR = 2.2, 95% CI 1.3-3.5; p < 0.05), advanced disease (for stage III, HR = 3.6, 95% CI 1.1-11.4; p < 0.05 and for stage IV, HR = 9.8, 95% CI 3.2-30.4, p < 0.001) and poor PS (for ECOG functional status 2, 3 and 4 the HR were 4.2, 4.5 and 32 respectively, all p values lower than 0.001). 
Discussion
Among diverse populations of patients suffering from chronic illnesses, characterization of sarcopenia and frailty has a growing significance (13, 14) . Nevertheless, objective, quantitative measures of frailty are missing and continuously pursued (15, 16) . Amongst cancer patients, frailty definition and evaluation has a growing interest. Brouwers and co. suggested plasma IL-6 as a potential marker of frailty in elderly breast cancer patients (17) . Sastre and co. offered that frailty may serve as a tool for selecting patients suffering from metastatic colorectal cancer for panitumumab treatment rather than chemotherapy (18) . Korc-Grodzicki and colleagues suggested that when deliberating surgical options for cancer patients, age by itself should not be a limiting factor and frailty assessment should determine the most appropriate treatment measures (4).
Regarding lung cancer patients, Soares and co. performed a prospective study in 449 patients trying to characterize those patients that would benefit the most from ICU admission (19) . Not surprisingly, they found that frail lung-cancer patients did not fit intensive treatment and were more suitable for palliative care. However, their method of evaluating frailty did not rely on any single quantitative parameter.
As the population of lung cancer patients ages, and as additional potentially life prolonging treatments become available, it becomes more important to define frailty among lung cancer patients. Using ALT levels as a quantitative measure for frailty, alongside with other existing qualitative measures, could potentially be of clinical relevance. Previous studies in both healthy middle aged adults and selected populations suffering from chronic diseases, showed that lower ALT values are associated with increased frailty and risk of earlier mortality (12, 20) . In these studies, patients presenting with higher-than-normal (> 40 IU/L) ALT values were excluded, since their ALT blood levels are associated not only with their whole body muscle mass, the major contributor for ALT in the blood, but possibly also with hepatocellular damage and resultant spillage of ALT out of hepatocytes.
Several studies support the hypothesis that within the normal range, ALT blood levels are associated with whole-body muscle mass. Accordingly, lower ALT values are associated with sarcopenia. Since ALT activity is also dependent upon sufficient activity of this enzyme's cofactor (P5P, Pyridoxal 5 Phosphate, and the active metabolite of Vitamin B6) it is also lowered in cases of Vitamin B6 deficiency. Lowered ALT activity is also found in patients with end stage renal disease (21, 22) and in patients suffering from Parkinson's disease on treatment with Levodopa formulations (23) .
In this study we did not find a statistically significant association between lowered ALT blood activity and shortened survival amongst patients with advanced lung cancer, unlike the case in the general populations and in patients with other morbidities. This finding might be explained by the fact that lung cancer is a rapidly progressive disease, and death might not be preceded by frailty, at least not the same frailty encountered in the general, aging population.
Conclusions
Patients suffering from advanced lung cancer have a shortened survival that is not correlated with the activity of their serum ALT. We speculate that lung-cancerassociated-frailty is not mediated by sarcopenia but by other pathophysiologic mechanisms. Other, quantitative parameters of frailty should be sought in a larger set of lung cancer patients' population.
